UNITED Scientific Group
A non-profit scientific organization

5TH INTERNATIONAL CONFERENCE ON DRUG DISCOVERY DEVELOPMENT AND LEAD OPTIMIZATION

Emmerging Disease Target Validation in Metabolism, Infectious Diseases, Cancer and Cannabis

Venue
Crowne Plaza Boston - Newton
320 Washington St, Newton, MA 02458

DRUG DISCOVERY-2019
November 21-23, 2019

Silver Sponsor

COVANCE
SOLUTIONS MADE REAL

Supporting Sponsor

SYNTHEGO

Venue Floor Plan

FIRST FLOOR



SECOND FLOOR



Welcome Message

It is my great pleasure as organizer and chairman to welcome everyone to the 2019, 5th International Drug Discovery Conference. I would like to begin by acknowledging Dr. Troels Koch, VP & Head of Research, RNA Therapeutics Roche Innovation Center Copenhagen Denmark as co-organizer and Mr. Satish Noolu as meeting coordinator from United Scientific Group for their critical input and assistance in organizing this meeting and website as well as generous sponsor support from Covance and Synthego. I would also like to thank the city Boston for hosting our meeting with their exceptional accommodations in the backdrop of this historic city and its cultural and high-tech ambiance. This year's conference emphasizes cutting-edge research and preclinical development being conducted globally by companies and contract research and academic laboratories. The goal of this conference series continues to be to encourage a dialog on ideation, collaboration and resource sharing. This three-day conference is structured around Plenary and Keynote addresses, five symposia and a poster session. Our plenary presentation by Dr. Carl Dieffenbach, Director of DAIDS, NIAD at the National Institutes of Health will evaluate the almost 40 year drug discovery effort in the battle to end HIV. Following the morning plenary presentation on the first day, the conference will dive into five symposia consisting of scientists and opinion leaders on the topics of: 1. emergent drug development approaches and opportunities, 2. emerging drug development for cannabis, 3. nucleic acids as drugs, drug targets and gene editing tools, 4. drug development for infectious disease and immune modulation and 5. oncology drug target validation. The range of topics covered by speakers in each symposium will be lead by keynote presentations from Drs. Lawrence Vernetti, Director of Early Stage Drug Safety, University of Pittsburgh, Ethan Russo, Director of R&D, International Cannabis and Cannabinoid Institute, Bo Rode Hansen, President and CEO of Genevant Sciences, Paul Dunman, Professor at the University of Rochester, School of Medicine and Dentistry and Ives Pommier, Chief for Developmental Therapeutics, NIH. In these keynote addresses we will learn of diverse critical paths that can be taken in drug discovery and lead optimization in both established drug discovery areas as well as emerging opportunities. The meeting plan is to afford amply time for informal networking, brain storming and dynamic conversations over posters. I look forward to meeting you and sharing our collective talents at this very exciting, informative and interactive conference.



Harold C. Smith, Ph.D
Conference Chairman - Drug Discovery-2019

Department of Biochemistry and Biophysics
Medical Center, Cancer Center and Center for RNA Biology
University of Rochester, School of Medicine and Dentistry
Rochester, NY

Conference Chairman

Harold C. Smith, Ph.D

Conference Chairman - Drug Discovery-2019

Department of Biochemistry and Biophysics
Medical Center, Cancer Center and Center for RNA Biology
University of Rochester, School of Medicine and Dentistry
Rochester, NY

Dr. Smith earned his M.A. and Ph.D. from SUNY at Buffalo, following earning his B.S. and M.S. degrees from Purdue University. His postdoctoral research was conducted at Baylor College of Medicine. He is a full Professor in Biochemistry, Biophysics at the University of Rochester, School of Dentistry and Medicine, and is a Member of the University's Cancer Center and Center for RNA Biology. Dr. Smith's research has been supported through grants from the NIH and Bill and Melinda Gates Foundation, the United States Air Force and the Office of Naval Research. He is the author of more than 141 peer-reviewed manuscripts and reviews during his career, exceeding more than 9,973 citations. He is a member of the RNA Society, American Society for Biochemistry and Molecular Biology and International Society for Antiviral Research. He received the SUNY at Buffalo's Distinguished Alumni Award as well as several teaching and mentoring awards from the University of Rochester. Dr. Smith is an opinion leader in RNA and DNA editing. He established the first in an ongoing Gordon Research Conference series on RNA and DNA Editing and Modification. In 2003, Dr. Smith founded OyaGen, Inc. The company's current leads are in preclinical development as first-in-class antiviral therapeutics for HIV and Ebola. In 2016, Dr. Smith founded CannaMetrix, LLC with the goal of establishing human cell-based, high throughput assays to quantify cannabis product potency and consistency using biological standards

Conference Co-Chairman

Troels Koch, M.Sc., Ph.D.

Conference Co-Chairman - Drug Discovery 2019
VP & Head of Research, RNA Therapeutics
Roche Innovation Center Copenhagen
Denmark

Troels Koch (TK) has 20 years' experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.

SILVER SPONSOR



EARLY PHASE DEVELOPMENT SOLUTIONS

Making every day of your journey count

With so many different regulatory requirements and scientific challenges in the early stages of drug development, it can be difficult to navigate a way forward, easily. Discover a clear path with Early Phase Development Solutions. It's a programmatic approach for meeting your drug development goals that teams you up with drug development leaders to prospectively plan and execute the required studies in an expedited way. By making every day of the journey count, Early Phase Development Solutions has helped hundreds of biotech firms reach their program goal up to 30 percent faster over the past three years.

BEGIN WITH THE END IN SIGHT

Start off on the right track

Your vision for your molecule defines your entire program. From your development team and strategy to your contracts and financing, everything is customizable to your requirements.

Stay on course

Keep up to date on the details and progress of your program with regular status updates on your program timeline and proactive reports on potential risks to your candidate's development.

Achieve your program milestone

Reach your clinical goal faster with an approach that eliminates white space in your early drug development timeline and streamlines your transition from nonclinical to clinical development.

COVANCE®
SOLUTIONS MADE REAL®

HOW FAR YOU GO IS UP TO YOU

Whether you plan to complete an IND/CTA-enabling program or you need to gain the clinical insight that a first-in-human (FIH) or proof-of-concept (PoC) study can provide, you can enjoy the journey with a dedicated team and a singular, cohesive strategy.



Real-world benefits of a time-tested approach

Join more than 225 biotech ventures that have experienced the real-world benefits of a programmatic approach over the course of the past three years.

PARTNERSHIP

A dedicated team that's with you for the entire journey

Collaborate with a Drug Development Leader and a Certified Project Manager at the helm of your program

Gain specialized expertise in nonclinical, clinical and regulatory, as you need it

De-risk your molecule development with a team that proactively monitors your program

CONTINUITY

A proactive strategy, from start to finish

Get an integrated development plan that minimizes time between studies

Stay up to date through regular communications with your team

Transition seamlessly from nonclinical into clinical development

VALUE

An integrated and streamlined approach that adds value to your asset

See your estimated total program timeline and cost up front

Select a flexible financial model that fits your goals

Reach critical milestone dates on time

Obtain valuable clinical insight by taking your program all the way through FIH or PoC

READY TO ACCELERATE YOUR JOURNEY THROUGH DRUG DEVELOPMENT?
TAKE THE CLEAR PATH FORWARD WITH EARLY PHASE DEVELOPMENT SOLUTIONS.

The Americas +1.888.COVANCE | Europe/Africa +00.800.2682.2682
Asia Pacific +800.6568.3000 | Or go to covance.com/epds

COVANCE®
SOLUTIONS MADE REAL®

Day One

Nov 21
Thursday

8:00 - 9:00 Registrations

09:00 - 09:10 Introduction and Welcome address by Conference Chairman - Prof. Harold Smith, Rochester University, New York, NY

Plenary Talk Talk: 30 Min | Q&A: 10 Min

Carl Dieffenbach **09:10**
National Institutes of Health, Bethesda, MD

***Title:* Drug Development for HIV: We Have Come So Far, and We Are Not Yet Done**

Carl W. Dieffenbach, Ph.D., serves as Director of the Division of AIDS (DAIDS). Dr. Dieffenbach oversees a global HIV/AIDS research portfolio of more than $1 billion and a staff of more than 150 federal employees. He played a key role in restructuring the DAIDS-supported clinical trials research networks and has actively fostered collaboration and partnerships with other federal agencies, international research organizations, foundations, and industry. In 1992, he joined DAIDS as the chief of the preclinical therapeutics group. Upon his appointment, Dr. Dieffenbach spearheaded important research initiatives that accelerated the progress of basic research on HIV pathogenesis and directly resulted in new clinical studies of novel AIDS therapies. In 1996, he was promoted to Director of the DAIDS Basic Sciences Program, where he remained until being selected as the division director in 2008. In 2011, Dr. Dieffenbach received the Distinguished Alumnus Award of the Department of Chemistry and Biochemistry, University of Maryland.

09:50 **Refreshment Break**

Symposium I: Emergent Drug Development Approaches and Opportunities

Co-Chairman: *Lawrence Vernetti, University of Pittsburgh, Pittsburgh, PA*
Marina Seme-Nelson, Covance Inc., Madison, WI

Keynote Talk (Talk: 25 Min | Q&A: 5 Min)

Lawrence Vernetti **10:10**
University of Pittsburgh, Pittsburgh, PA

***Title:* Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Discovery Through the Application of Quantitative Systems Pharmacology and Microphysiology Systems**



Lawrence Vernetti, Ph.D. currently working as Research Associate Professor in the department of Computational and Systems Biology and he is the Director of Early Drug Safety, University of Pittsburgh Drug Discovery Institute, PA. Before joining University of Piitsburgh he worked as Director of Cellular Toxicology at Cellumen from 2007-2010 and as a Research Scientist at Abbott Laboratories during 1992-2007. He completed his Ph.D in the year 1992 from University of Arizona, Tucson, AZ. His research focus is in the application of early drug safety testing using a variety of in vitro, in vivo and in silico methodologies.

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

10:40 Marina Seme-Nelson, Covance Inc., Madison, WI
Bridging the Gap: IND to FIH and Beyond

11:05 Stephanie C. Oestreich, EVP, Head BRIDGEs Partnerships North America, Evotec
Path to IND – How to Use Partners to Create Valuable Data for a Startup

11:30 Adam Simon, Qulab Inc., Los Angeles, CA
AI-Automated De Novo Small Molecule Design

11:55 Ravindra Peravali, Karlsruhe Institute of Technology, Germany
Using Zebrafish Embryonic and Larval Behavior for Drug Discovery and Testing

12:20 Michael Graziano, TARA Biosystems, Inc., New York, NY
Cardiotype SM Engineered Cardiac Tissues: An iPSC Derved Human-Relevant Model for Drug Discovery and Development

12:45 Lunch & Networking

13:45 Robert Ricciardi, University of Pennsylvania, PA
Developing a Novel Drug to Treat Herpes Ocular Keratitis, the Leading Cause of Ocular Blindness in the World

14:10 TBA
TBA

Short Talk (Talk: 12 Min | Q&A: 3 Min)

14:35 Pradeep Karla, Howard University, Washington, D.C.
Drug Efflux Transporters - Targets for HIV Drug Delivery?

14:50 Helen Yu, Centre for Advanced Studies in Biomedical Innovation Law, University of Copenhagen, Denmark
Leveraging Research Failures to Accelerate Drug Discovery and Development

Symposium II: Emerging Drug Development for Cannabis

Co-Chairman *Ethan Russo, International Cannabis and Cannabinoids Institute, Czech Republic, EU*
Dana M. Lambert, Andira Pharmaceuticals, Vancouver, Canada

Keynote Talk **(Talk: 25 Min | Q&A: 5 Min)**

Ethan Russo **15:05**
International Cannabis and Cannabinoids Institute, Czech Republic, EU

Title: Pharmacochemistry of Cannabis, a Whirlwind Tour

Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic. Previously, he was Medical Director of PHYTECS (2015-2017) and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom. He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He has also published numerous book chapters, and over 50 articles in neurology, pain management, cannabis, and ethnobotany. He has consulted or lectured in 39 US states and Canadian provinces and 39 countries.

Day :: One

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

15:35 David M. Lovinger, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD
Cannabinoid Drugs and Endocannabinoids in Behavioral Disorders and Addiction

16:00 Refreshment Break

16:20 Igor Kovalchuk, University of Lethbridge, Canada
Breeding Cannabis with Specific Medicinal Properties

16:45 Klaus Gawrisch, NIAAA, NIH, Bethesda, MD
Pharmacology of Cannabinoid Ligands and Ligand-Induced Changes of Receptor Structure

17:10 Dana M. Lambert, Andira Pharmaceuticals, Vancouver, Canada
Addressing Synergy Versus Antagonism in Botanical-Based Pharmaceutical Development

17:35 Alexandros Makriyannis, Northeastern University, Boston, MA
Structure and Function of the CB1 and CB2 Cannabinoid Receptor Targets for Novel Medications

18:00 Wine Reception & Poster Session

18:00 Poster Session

P-01 Nicole Pouli, National and Kapodistrian University of Athens, Greece
Design and Synthesis of New Modified Purines with Potent Antiproliferative Activity

P-02 Panagiotis Marakos, National and Kapodistrian University of Athens, Greece
Design and Synthesis of New 5-arylcarboximidamidopyrazolo[3,4-c]pyridines with Antiproliferative Activity

P-03 Pradeep Karla, Howard University, Washington, D.C.
Brinzolamide Nanoparticles for Improved Glaucoma Drug Delivery

P-04 Karl Gatterdam, University Clinics Bonn - Institute of Structural Biology, Germany
Early Stage Research by Surface Plasmon Resonance Spectroscopy

P-05 Ujjayinee Ray, Department of Biochemistry, Indian Institute of Science, India
Novel Inhibitors of Nonhomologous End Joining: Identification, Biochemical Characterisation and Insights into Cancer Therapeutics

P-06 Pradeep Karla, Howard University, Washington, D.C.
Thermoreversible Nano Tenofovir Microbicide for HIV

P-07 Saud Bawazeer, College of Pharmacy, Umm Al-Qura University, Saudi Arabia
Design, Synthesis and Biological Evaluation of Mannose Based Glycodendrimers as Potent DC-Sign Antagonists for Dengue Infection

P-08 Dunpeng Cai, University of Georgia, Athens, GA
TBA

P-09 Murtala A. Ejalonibu, University of KwaZulu-Natal, Durban, South Africa
Dual Mtb PanK/PyrG Inhibition: Insights from Comparative Molecular Dynamics and Binding Free Energy Analyses

Day :: One

P-10 Ibrahim M. Moustafa, The Pennsylvania State University, PA
Detection of Novel Small-Molecule Binding Site on the Viral Capsid Protein VP3 of Coxsackievirus B3 and Identification of Candidate Inhibitors by Virtual Screening

P-11 Joel Frandsen, University of Nebraska Medical Center, Omaha, Nebraska
Morin Derivatives on Neural Glyoxalase Pathway Enhancement in an Oxidative Stress Model of Alzheimer's Disease

P-12 Prasanthi Medarametla, University of Eastern Finland, Helsinki, Finland
Computational Approaches in Identification of Lsrk Inhibitors Targeting Quorum Sensing

P-13 Lisa L. Hester, Flowered Wellness, LLC., Orchard Park, NY
Bridging the Gap; A Proposal to Facilitate and Accelerate the Transition of Cannabis Research to Clinical Practice

P-14 Cynthia Lichorowic, Aerie Pharmaceuticals, Inc., Durham, NC
Synthesis and Development of New, Potent JAK Inhibitors for the Treatment of Ocular Indications

P-15 Marie Wiik, Recipharm OT Chemistry, Uppsala, Sweden
Successful Collaboration between Recipharm OT Chemistry and Oncopeptides AB in the Development of Melflufen, a Peptidase-Potentiated Alkylating Agent in Clinical Trials

Short Talks & Poster Slots Available

Nov 21
Thursday

Day ... TWO

Nov 22
Friday

Symposium III: Nucleic Acids as Drugs, Drug Targets and Gene Editing Tools

Co-Chairman *Troels Koch, Roche Innovation Center Copenhagen, Denmark*
Bo Rode Hansen, Genevant Sciences, Boston, MA

Keynote Talk (Talk: 25 Min | Q&A: 5 Min)

Bo Rode Hansen **08:30**
Genevant Sciences, Boston, MA

Title: TBA

Bo Rode Hansen, MBA, PhD joined Genevant in October 2018, taking on the roles of President and Chief Executive Officer in November 2018. Previously, Bo served as Global Head of RNA Therapeutics and General Manager of the Roche Innovation Center Copenhagen. Prior to Roche, he was Executive Vice President and Head of Drug Discovery & Alliance Management at Santaris Pharma (acquired by Roche). He is a Pioneer in RNA therapeutics and has led multiple discovery programs translating into clinical candidates in the areas of oncology, infectious diseases, rare genetic-, neurological- and metabolic disorders. He holds a PhD from Kobenhavns Universitet, an MS in Biochemistry from the University of Copenhagen and a BS from Universita Degli Studi di Pavia.

Brian Schneider **09:00**
Synthego, Redwood City, CA

Title: Optimizing CRISPR Gene Editing Tools for Drug Discovery

Brian Schneider, Ph.D is the Senior Territory Account Manager at Synthego Corporation, Boston, MA. Before joining Synthego Inc., he worked as Director, Strategic Accounts at Gen9 In., from 2015-16, and as Area Business Director at CyVek during 2014 and as Corporate Account Manager at Roche from 2011-2014. He graduated from Massachusetts Institute of Technology (MIT) in 1999.

09:30 **Refreshment Break**

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

09:50 Sven Korte, Covance Preclinical Services GmbH, Münster, Germany
Conduct and Design of Nonhuman Primate Studies for First in Man (FIM) and beyond. Oligos: Non Systemic Delivery – Rare and Orphan

10:15 Alexander McCampbell, Biogen, Boston, MA
Antisense Oligonucleotides as an Emerging Modality for the Treatment of Neuromuscular Diseases

10:40 Søren Warming, Genentech, Inc., San Francisco, CA
CRISPR Off-Target Analysis in Genetically Engineered Rodents

11:05 Norbert Pardi, University of Pennsylvania, Philadelphia, PA
Development of New Generation Vaccines using Nucleoside-Modified mRNA

Day :: TWO

Nov 22
Friday

11:30 David Butler, Wave Life Sciences, Medford, MA
Control of Backbone Stereochemistry Provides a New Dimension for the Optimization of Oligonucleotide Drug Candidates

11:55 David Evans, Sirnaomics, Inc., Cambridge, MA
Discovery and Development of the Novel RNAi Therapeutics to Treat Cancer and Fibrosis

12:20 Andrea Kasinski, Purdue University, West Lafayette, IN
Ligand-Conjugated Delivery of Therapeutic microRNAs

12:45 Lunch & Networking

Symposium IVa: Drug Development for Infectious Disease and Immune Modulation

Co-Chairman *Paul Dunman, University of Rochester Medical Center, Rochester, NY*
Anna Jacobs, Walter Reed Army Institute of Research, Silver Spring, MD

Keynote Talk (Talk: 25 Min | Q&A: 5 Min)

Paul Dunman **13:45**
University of Rochester Medical Center, Rochester, NY

Title: TBA

Paul Dunman, Ph.D. is the Principal Investigator in the School of Medicine and Dentistry and Associate Professor in the Department of Microbiology and Immunology (SMD) at University of Rochester Medical Center, Rochester, NY. He completed his Ph.D from University of Medicine and Dentistry-NJ (UMDNJ) in 1999 and Post-doctoral studies in the year 2001. He has received Young Investigator of the Year award in 2003a and Distinguished Investigator award in 2010 from University of Nebraska Medical Center.

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

14:15 Shuji Ogino, Harvard Medical School, Boston, MA
Integrative Analyses of Environment, Microbiome, Genomics, and Immunity for Precision Medicine

14:40 Thomas Webster, Northeastern University, Boston, MA
Are Nanoparticles Suitable Drug Substitutes ? Fighting Infection, Inhibiting Cancer, and Growing Tissues

15:05 Anna Jacobs, Walter Reed Army Institute of Research, Silver Spring, MD
TBA

15:30 Rachel Wozniak, University of Rochester Medical Center, NY
Development of a Broad Spectrum Antimicrobial Combination for the Treatment of Ocular Infections

15:55 Refreshment Break

Day ... TWO

16:15 Cynthia Dowd, George Washington University, Washington, DC
MEPicides as Promising Antimicrobials

16:40 Yan Yuan, University of Pennsylvania, Philadelphia, PA
An mTORC2 Inhibitor Reveals A Crucial Role of mTORC2 Signaling in Epstein-Barr Virus Lytic Replication and Tumorigenesis

17:05 Mu Yuguang, Nanyang Technological University, Singapore
Binding Modes of Teixobactin to Lipid II: Molecular Dynamics Study

Short Talks & Poster Slots Available

Nov 22
Friday

Symposium IVb: Drug Development for Infectious Disease and Immune Modulation

Co-Chairman *Paul Dunman, University of Rochester Medical Center, Rochester, NY*
Anna Jacobs, Walter Reed Army Institute of Research, Silver Spring, MD

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

8:00 Douglas K. Graham, Aflac Cancer and Blood Disorders Center, Atlanta, GA
TBA

8:25 Ourania M. Andrisani, Purdue University College of Veterinary Medicine, West Lafayette, IN
MicroRNA Inhibitors Rescuing RNA Helicase DDX5 as Hepatitis B Virus (HBV) Antiviral and Anti-tumor Tools

8:50 Catherine Adamson, University of St Andrews, St Andrews, Scotland
Modular Cell-based Platform for High Throughput Identification of Compounds that Inhibit a Viral Interferon Antagonist of Choice

9:15 Ryan Bennett, OyaGen, Inc., Rochester, NY
Enabling APOBEC Innate Antiviral Immunity through HIV Vif Antagonists

9:40 Helen I. Zgurskaya, University of Oklahoma, Norman, OK
Antitubercular Compounds

10:05 Refreshment Break

Symposium V: Oncology Drug Target Validation

Co-Chairman *Yves Pommier, Chief, Developmental Therapeutics Branch, NIH, Bethesda, MD*
Liang Tong, Columbia University, New York, NY
Annette M. Tobia, Dynamis Pharmaceuticals, Inc., Jenkintown, PA

Keynote Talk (Talk: 25 Min | Q&A: 5 Min)

Yves Pommier **10:25**
Chief, Developmental Therapeutics Branch, NIH, Bethesda, MD

Title: Cancer Cell Line Pharmacogenomic Databases Integration in CellMiner for Drug and Response Predictor Discover

Dr. Pommier received his M.D. and Ph.D. degrees from the University of Paris, France, and has been at the NIH since 1981. Dr. Pommier is the chief of the Developmental Therapeutics Branch (formerly the Laboratory of Molecular Pharmacology), the co-chair of the Discovery Committee of the NCI Experimental Therapeutics Program and member of the Molecular Target steering committee at the Center for Cancer Research, NCI. Dr. Pommier is also honorary professor of the Shanghai Institute Materia Medica, Chinese Academy of Sciences and adjunct member of the NCI Developmental Therapeutics Program (NCI-DTP). Dr. Pommier has received an NIH Merit Award for his role in elucidating the function of topoisomerases as targets for anticancer drugs and Federal Technology Transfer awards for studies on HIV-1 integrase and DNA topoisomerase inhibitors. Dr. Pommier received the Paul Ehrlich Lecture Award from the Societe de Chimie Therapeutique in 2005. Dr. Pommier has authored more than 550 publications and holds over 20 patents for inhibitors of DNA topoisomerases, tyrosyl-DNA phosphodiesterase, checkpoint inhibitors and HIV-1 integrase inhibitors.

Day :: THREE

Nov 23
Saturday

Symposium Talks (Talk: 20 Min | Q&A: 5 Min)

10:55 Elmar Nurmemmedov, John Wayne Cancer Institute, Santa Monica, CA
Wnt Pathway: A Hallmark of Drug Discovery Challenge

11:20 Timothy Ratliff, Purdue University Center for Cancer Research, West Lafayette, IN
Targeting Myeloid Cells in the Tumor Microenvironment

11:45 Maurizio Pellecchia, UCR School of Medicine, CA
Targeting Protein-protein Interactions using Biophysics-Guided Ligand Design Strategies

12:10 Annette M. Tobia, Dynamis Pharmaceuticals, Inc., Jenkintown, PA
A Sugar-driven Enzymatic Pathway that Results in Inflammation and Glycation and the Effects of Inhibiting it

12:35 Deborah W. Knapp, Purdue University College of Veterinary Medicine, West Lafayette, IN
Advancing Predictive Modeling in Cancer Drug Discovery through Incorporation of Naturally-Occurring Canine Cancer Models

13:00 Lunch & Networking

14:00 Paul C. Trippier, University of Nebraska Medical Center, Omaha, NE
Small Molecule AKR1C3 Inhibitors Counter Drug Resistance in Hematological and Solid Cancers

14:25 Paolo Lombardi, Naxospharma S.R.L., Novate Milanese MI, Italy
Berberine: An Epiphany Against Cancer?

14:50 Liang Tong, Columbia University, New York, NY
An Allosteric Mechanism for Potent Inhibition of Human ATP-citrate Lyase

15:15 Weike Mo, Digital China Health, Clinical and Genomic Data Services, China
Oncology Big Data For Drug Discovery: A Combination of Artificial Intelligence, Medical Informatics and Bio-Informatics

15:40 Hanumappa Ananda, Adichunchanagiri University, Mandya, India
Discovery and Pharmacological Description of a Novel Topoisomerase II Inhibitor, ASR6 as a Potent Chemotherapeutic Agent

Short Talk (Talk: 12 Min | Q&A: 3 Min)

16:05 Tinghu Zhang, Dana-Farber Cancer Institute, Boston, MA
Degradation of CDK protein by PROTAC

16:20 Sathees C. Raghavan, Indian Institute of Science Bangalore, India
BCL2 Specific Inhibitor, Disarib and Its Derivatives as a Potent Cancer Therapeutic Agent

16:35 Taleb H. Al-Tel, University of Sharjah, Sharjah, UAE
The Visual Seeing of the Third Dimension as a Powerful Tool for Drug Discovery Campaign: Discovery of Novel Lead Drug Candidates for Cancer Immunotherapy

16:50 Concluding Remarks & Thanks

17:00 Refreshments & Departures

NOTE: *This is a Tentative program and subjected to change

We wish to see you at Drug Discovery-2020

UNITED Scientific Group
A non-profit scientific organization

8105, Rasor Blvd - Suite #112, PLANO, TX 75024, USA
Ph: +1-408-426-4832, +1-408-426-4833; **Toll Free:** +1-844-395-4102; Fax: +1-408-426-4869
Email: drugdiscovery@uniscigroup.org; contact@usadrugdiscovery.com
Web: www.unitedscientificgroup.com/conferences/drug-discovery/